Related references
Note: Only part of the references are listed.Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D. S. Boss et al.
ANNALS OF ONCOLOGY (2010)
A Synthetic Cell-Penetrating Peptide Antagonizing TrkA Function Suppresses Neuropathic Pain in Mice
Wei-Ying Ma et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2010)
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
Clara Albanese et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
Kamila B. Kurakhmaeva et al.
JOURNAL OF DRUG TARGETING (2009)
Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
Maria Gabriella Brasca et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
TrkA overexpression enhances growth and metastasis of breast cancer cells
C. Lagadec et al.
ONCOGENE (2009)
The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain
F. De Conno et al.
PALLIATIVE MEDICINE (2008)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Manipulation of the nerve growth factor network in prostate cancer
Athanasios G. Papatsoris et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Clinical relevance of the neurotrophins and their receptors
SJ Allen et al.
CLINICAL SCIENCE (2006)
Oncogenic rearrangements of the NTRK1/NGF receptor
MA Pierotti et al.
CANCER LETTERS (2006)
Expression of neurotrophin receptors in surgically resected thymic epithelial tumors
DJ Kim et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2005)
Analysis of cell cycle regulator proteins in encapsulated thymomas
A Baldi et al.
CLINICAL CANCER RESEARCH (2005)
Clinical anticancer drug development: targeting the cyclin-dependent kinases
C Benson et al.
BRITISH JOURNAL OF CANCER (2005)
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
JL Marshall et al.
INVESTIGATIONAL NEW DRUGS (2005)
Mouse development and cell proliferation in the absence of D-cyclins
K Kozar et al.
CELL (2004)
Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer
X Montano et al.
FEBS LETTERS (2004)
Living with or without cyclins and cyclin-dependent kinases
CJ Sherr et al.
GENES & DEVELOPMENT (2004)
Cdk2 knockout mice are viable
C Berthet et al.
CURRENT BIOLOGY (2003)
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
S Ortega et al.
NATURE GENETICS (2003)
To cycle or not to cycle: A critical decision in cancer
M Malumbres et al.
NATURE REVIEWS CANCER (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
